C WorldWide Group Holding A S Has $3.63 Million Holdings in Dynavax Technologies Co. (DVAX)

C WorldWide Group Holding A S raised its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 1.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 496,412 shares of the biopharmaceutical company’s stock after purchasing an additional 6,049 shares during the quarter. C WorldWide Group Holding A S’s holdings in Dynavax Technologies were worth $3,629,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Wells Fargo & Company MN lifted its stake in shares of Dynavax Technologies by 6.0% during the 3rd quarter. Wells Fargo & Company MN now owns 87,721 shares of the biopharmaceutical company’s stock worth $1,087,000 after purchasing an additional 4,979 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Dynavax Technologies by 1.4% during the 3rd quarter. BlackRock Inc. now owns 4,123,662 shares of the biopharmaceutical company’s stock worth $51,134,000 after purchasing an additional 56,568 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Dynavax Technologies by 1.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 264,669 shares of the biopharmaceutical company’s stock worth $3,282,000 after purchasing an additional 4,591 shares during the last quarter. MetLife Investment Advisors LLC lifted its stake in shares of Dynavax Technologies by 55.5% during the 3rd quarter. MetLife Investment Advisors LLC now owns 44,609 shares of the biopharmaceutical company’s stock worth $553,000 after purchasing an additional 15,919 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Dynavax Technologies by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,883,887 shares of the biopharmaceutical company’s stock worth $35,759,000 after purchasing an additional 29,898 shares during the last quarter. Institutional investors own 83.95% of the company’s stock.

Shares of NASDAQ:DVAX opened at $7.69 on Friday. Dynavax Technologies Co. has a 1 year low of $6.22 and a 1 year high of $20.10. The stock has a market cap of $452.85 million, a P/E ratio of -3.02 and a beta of 0.60. The company has a current ratio of 4.58, a quick ratio of 4.08 and a debt-to-equity ratio of 1.60.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.05. Dynavax Technologies had a negative return on equity of 139.00% and a negative net margin of 1,938.27%. The company had revenue of $5.77 million for the quarter, compared to analyst estimates of $5.95 million. During the same period in the prior year, the company posted ($0.63) EPS. The firm’s quarterly revenue was up 3294.1% compared to the same quarter last year. Research analysts expect that Dynavax Technologies Co. will post -2.22 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. ValuEngine cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Finally, BidaskClub upgraded Dynavax Technologies from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $27.00.

In related news, insider Michael S. Ostrach sold 35,444 shares of the company’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $8.94, for a total transaction of $316,869.36. Following the transaction, the insider now directly owns 121,581 shares of the company’s stock, valued at approximately $1,086,934.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Robert Coffman sold 63,202 shares of the company’s stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $9.03, for a total value of $570,714.06. Following the transaction, the senior vice president now directly owns 86,268 shares in the company, valued at $779,000.04. The disclosure for this sale can be found here. Insiders have sold a total of 119,411 shares of company stock worth $1,075,091 over the last ninety days. 3.47% of the stock is currently owned by corporate insiders.

WARNING: This news story was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/10/c-worldwide-group-holding-a-s-has-3-63-million-holdings-in-dynavax-technologies-co-dvax.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Featured Story: Short Selling – Explanation For Shorting Stocks

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.